drugset / Trial / NCT05436223
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.
Timeline
- Start
- 2021-08-09
- Primary completion
- 2024-08-09
- Completion
- 2026-08-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Human CD19Targeted T Cells Injection | Cell therapy | 2e+06 cells/kg | — |